BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

540 related articles for article (PubMed ID: 26390847)

  • 1. Index lesion characterization by (11)C-Choline PET/CT and Apparent Diffusion Coefficient parameters at 3 Tesla MRI in primary prostate carcinoma.
    Hernández-Argüello M; Quiceno H; Pascual I; Solorzano JL; Benito A; Collantes M; Rodríguez-Fraile M; Pardo J; Richter JA
    Prostate; 2016 Jan; 76(1):3-12. PubMed ID: 26390847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is there an additional value of ¹¹C-choline PET-CT to T2-weighted MRI images in the localization of intraprostatic tumor nodules?
    Van den Bergh L; Koole M; Isebaert S; Joniau S; Deroose CM; Oyen R; Lerut E; Budiharto T; Mottaghy F; Bormans G; Van Poppel H; Haustermans K
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1486-92. PubMed ID: 22284686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective evaluation of 11C-choline positron emission tomography/computed tomography and diffusion-weighted magnetic resonance imaging for the nodal staging of prostate cancer with a high risk of lymph node metastases.
    Budiharto T; Joniau S; Lerut E; Van den Bergh L; Mottaghy F; Deroose CM; Oyen R; Ameye F; Bogaerts K; Haustermans K; Van Poppel H
    Eur Urol; 2011 Jul; 60(1):125-30. PubMed ID: 21292388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preoperative lymph node staging in patients with primary prostate cancer: comparison and correlation of quantitative imaging parameters in diffusion-weighted imaging and 11C-choline PET/CT.
    Vag T; Heck MM; Beer AJ; Souvatzoglou M; Weirich G; Holzapfel K; Rummeny EJ; Schwaiger M; Krause BJ; Eiber M
    Eur Radiol; 2014 Aug; 24(8):1821-6. PubMed ID: 24889997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of apparent diffusion coefficient and MR volumetry as independent associative factors for extra-prostatic extension (EPE) in prostatic carcinoma.
    Lim C; Flood TA; Hakim SW; Shabana WM; Quon JS; El-Khodary M; Thornhill RE; El Hallani S; Schieda N
    J Magn Reson Imaging; 2016 Mar; 43(3):726-36. PubMed ID: 26303719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate cancer: 1HMRS-DCEMR at 3T versus [(18)F]choline PET/CT in the detection of local prostate cancer recurrence in men with biochemical progression after radical retropubic prostatectomy (RRP).
    Panebianco V; Sciarra A; Lisi D; Galati F; Buonocore V; Catalano C; Gentile V; Laghi A; Passariello R
    Eur J Radiol; 2012 Apr; 81(4):700-8. PubMed ID: 21330082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate cancer: utility of diffusion-weighted imaging as a marker of side-specific risk of extracapsular extension.
    Rosenkrantz AB; Chandarana H; Gilet A; Deng FM; Babb JS; Melamed J; Taneja SS
    J Magn Reson Imaging; 2013 Aug; 38(2):312-9. PubMed ID: 23238968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the Added Value of Diffusion-Weighted Imaging to Conventional Magnetic Resonance Imaging in Pancreatic Neuroendocrine Tumors and Comparison With 68Ga-DOTANOC Positron Emission Tomography/Computed Tomography.
    Farchione A; Rufini V; Brizi MG; Iacovazzo D; Larghi A; Massara RM; Petrone G; Poscia A; Treglia G; De Marinis L; Giordano A; Rindi G; Bonomo L
    Pancreas; 2016 Mar; 45(3):345-54. PubMed ID: 26418904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Whole-Tumor Quantitative Apparent Diffusion Coefficient Histogram and Texture Analysis to Predict Gleason Score Upgrading in Intermediate-Risk 3 + 4 = 7 Prostate Cancer.
    Rozenberg R; Thornhill RE; Flood TA; Hakim SW; Lim C; Schieda N
    AJR Am J Roentgenol; 2016 Apr; 206(4):775-82. PubMed ID: 27003049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Final analysis of a prospective trial on functional imaging for nodal staging in patients with prostate cancer at high risk for lymph node involvement.
    Van den Bergh L; Lerut E; Haustermans K; Deroose CM; Oyen R; Isebaert S; Budiharto T; Ameye F; Mottaghy FM; Bogaerts K; Van Poppel H; Joniau S
    Urol Oncol; 2015 Mar; 33(3):109.e23-31. PubMed ID: 25655681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diffusion-weighted MRI,
    Kitajima K; Yamamoto S; Kawanaka Y; Nakanishi Y; Yamada Y; Go S; Kanematsu A; Kaida H; Yamakado K
    Hell J Nucl Med; 2020; 23(1):34-39. PubMed ID: 32222730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of multifocality and axillary nodal involvement in early-stage breast cancer patients using 18F-FDG PET/CT compared to contrast-enhanced and diffusion-weighted magnetic resonance imaging and sentinel node biopsy.
    Ergul N; Kadioglu H; Yildiz S; Yucel SB; Gucin Z; Erdogan EB; Aydin M; Muslumanoglu M
    Acta Radiol; 2015 Aug; 56(8):917-23. PubMed ID: 25013091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of Diffusion Kurtosis Imaging Versus Standard Diffusion Imaging for Detection and Grading of Peripheral Zone Prostate Cancer.
    Roethke MC; Kuder TA; Kuru TH; Fenchel M; Hadaschik BA; Laun FB; Schlemmer HP; Stieltjes B
    Invest Radiol; 2015 Aug; 50(8):483-9. PubMed ID: 25867657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection and localization of prostate cancer: correlation of (11)C-choline PET/CT with histopathologic step-section analysis.
    Farsad M; Schiavina R; Castellucci P; Nanni C; Corti B; Martorana G; Canini R; Grigioni W; Boschi S; Marengo M; Pettinato C; Salizzoni E; Monetti N; Franchi R; Fanti S
    J Nucl Med; 2005 Oct; 46(10):1642-9. PubMed ID: 16204714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of [(11)C]choline Positron Emission Tomography With T2- and Diffusion-Weighted Magnetic Resonance Imaging for Delineating Malignant Intraprostatic Lesions.
    Chang JH; Lim Joon D; Davis ID; Lee ST; Hiew CY; Esler S; Gong SJ; Wada M; Clouston D; O'Sullivan R; Goh YP; Bolton D; Scott AM; Khoo V
    Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):438-45. PubMed ID: 25864171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative prediction of neurovascular bundle involvement of localized prostate cancer by combined T2 and diffusion-weighted imaging of magnetic resonance imaging, number of positive biopsy cores, and Gleason score.
    Naiki T; Okamura T; Nagata D; Mori Y; Kawai N; Ogawa K; Akita H; Hashimoto Y; Tozawa K; Kohri K
    Asian Pac J Cancer Prev; 2011; 12(4):909-13. PubMed ID: 21790224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 11C-choline positron-emission tomography/computed tomography and transrectal ultrasonography for staging localized prostate cancer.
    Rinnab L; Blumstein NM; Mottaghy FM; Hautmann RE; Küfer R; Hohl K; Reske SN
    BJU Int; 2007 Jun; 99(6):1421-6. PubMed ID: 17355373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-invasive estimation of prostate cancer aggressiveness using diffusion-weighted MRI and 3D proton MR spectroscopy at 3.0 T.
    Thörmer G; Otto J; Horn LC; Garnov N; Do M; Franz T; Stolzenburg JU; Moche M; Kahn T; Busse H
    Acta Radiol; 2015 Jan; 56(1):121-8. PubMed ID: 24504488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imaging prostate cancer with 11C-choline PET/CT.
    Reske SN; Blumstein NM; Neumaier B; Gottfried HW; Finsterbusch F; Kocot D; Möller P; Glatting G; Perner S
    J Nucl Med; 2006 Aug; 47(8):1249-54. PubMed ID: 16883001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Whole-body diffusion-weighted magnetic resonance imaging (WB-DW-MRI) vs choline-positron emission tomography-computed tomography (choline-PET/CT) for selecting treatments in recurrent prostate cancer.
    Conde-Moreno AJ; Herrando-Parreño G; Muelas-Soria R; Ferrer-Rebolleda J; Broseta-Torres R; Cozar-Santiago MP; García-Piñón F; Ferrer-Albiach C
    Clin Transl Oncol; 2017 May; 19(5):553-561. PubMed ID: 27796820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.